The prevailing view is that there is an innovation and productivity crisis in the biopharmaceutical sector, with several factors cited in rote fashion as being causative. But is there really cause for concern, or are we just looking at a temporary blip in the industry’s development that will soon blow over?
Key topics covered:
- Effect of corporate size and productivity; the problem with mega-mergers - Is the science getting harder? (aka the 'easy fruit' argument) - The regulatory minefield - How is the industry going to get its innovation groove back? - Fostering small-company innovation - 'Arm's length' business models - The pharma spin-out strategy - Buying in innovation via M&A - Accessing academic innovation - Logging on to the networked world
